Mycoplasma haemofelis, Candidatus M. haemominutum, and Candidatus M. turicensis are the organisms responsible for hemoplasmosis. Virulence is attributed primarily to M. haemofelis and Candidatus M. turicensis. This disease has worldwide distribution with rates of prevalence varying from 4 percent to 23 percent for M. haemofelis, depending on the location. Since the flea is the likely vector, prevalence rates vary according to climate, too. Other modes
of transmission include blood transfusion (and by extension between cats if blood contamination occurs) and from the queen
to her kittens (in utero or via lactation).
Clinical signs are those associated with anemia, and fever often is present. Identification of the gram-negative, epierythrocytic
organisms on a blood smear is an unreliable means of diagnosis because of cyclic parasitemia, staining artifacts and sample
handling. PCR for organismal DNA is the most sensitive and specific test for the haemoplasma organisms. The standard treatment
is doxycycline (5 mg BID for 14 days), but there is substantial evidence that the fluoroquinolones are equally efficacious.
In several studies, enrofloxacin (5-10 mg PO q 24 hrs for 14 days), marbofloxacin (2.75 mg PO q24 hrs), and pradofloxacin
(a novel fluoroquinolone not yet available in the United States) have demonstrated clearance of the organism by PCR weeks
to months after therapy. In cats in which organism clearance has not occurred, recrudescence during times of stress is possible.
Cytauxzoon felis is a tick-borne protozoal organism that is predominantly found in the south central, southeastern and mid-Atlantic states.
The bobcat is the primary reservoir host and Dermacentor variabilis is the presumed tick vector. These signet ring-shaped organisms are located within the red blood cell during the "erythrocytic
phase" of the infection. C. felis invades monocytes/macrophages which are distributed to the tissue for the "tissue phase" or "leukocytic phase" of the disease.
Schizont-engorged monocytes clog vessels and account for the multi-organ failure and rapid death, usually within one week,
associated with cytauxzoonosis.
While anemia is considered 100 percent fatal in cats, recent reports of healthy carriers and cats that have survived suggest
that aggressive therapy may improve survival rates. A presumptive diagnosis often is made on acute onset of clinical signs
(severe lethargy, anorexia, icterus, dyspnea) in an endemic region with possible exposure to ticks. A definitive diagnosis
can be made if the parasite is visualized within the RBCs; PCR is also now available. A promising combination of the anti-malarial
drug atovaquone (15 mg/kg PO TID) and azithromycin (10 mg/kg PO Q24), in addition to aggressive supportive care and heparin,
is currently being recommended. With this combination, a survival rate of 64 percent was reported.
Bartonella species have been implicated in multiple diseases in humans, dogs and cats. In cats, the primary infective species are B. henselae and B. clarridgeiae. In humans, B. bacilliformis causes a hemolytic anemia in which nearly 100 percent of RBCs are infected. Although this organism does not infect cats,
a case of human hemolytic anemia caused by B. henselae has been reported.
Studies also have demonstrated the intraerythrocytic location of B. henselae in naturally infected cats using electron microscopy, making this organism a candidate for unexplained cases of feline anemia.
Recently, however, a retrospective study attempting to correlate Bartonella species with cases of hemolytic anemia found no significant prevalence differences in the healthy cats vs. anemic cats with
a positive Bartonella PCR assay.
As with many high-prevalence diseases, it will be difficult to make the association between Bartonella species and anemia.
Ehrlichia and Anaplasma-like DNA have been amplified from naturally-infected cats and have been demonstrated to cause clinical signs in cats, including
fever, lethargy, inappetence and, in some cases, anemia. Though these organisms are listed under hemolytic causes, the anemias
in one case report were non-regenerative. Given the fact that ehrlichiosis in cats is uncommon and that only some of these
cats had anemia, it is unnecessary to test routinely for these organisms in cats with anemia.
FeLV and FIV
FeLV can cause both non-regenerative and regenerative anemias. The latter may be due to concurrent infections with the haemoplasma
organisms, but an immune-mediated process is also possible. FeLV antigen testing is therefore recommended for any cat presenting
with hemolytic anemia. FIV infections are nearly always associated with a non-regenerative anemia. There are only a few controlled
studies evaluating use of antiviral agents in these diseases and most show either no effect or are toxic. Feline interferon-?
and human interferon-a showed some effect for FeLV and FIV, respectively.
Primary immune-mediated hemolytic anemia
There is a subset of cats with hemolytic anemia for which neoplasia, toxins and most infectious diseases have been ruled out,
either by infectious disease assays or trial therapies with anti-bacterial agents. In one study of 19 cats, no identifiable
infectious, neoplastic, or toxic could be found as a cause of their anemia.
A majority of these cats were Coombs' positive, suggesting that anti-erythrocyte antibodies were present. In another retrospective
study of anemic cats whose blood was submitted for extensive infectious-disease testing, approximately 75 percent of cats
with either non-regenerative or regenerative anemia and 60 percent with non-regenerative anemia were negative for all organisms
tested. This would suggest that primary immune-mediated hemolytic anemia may be more common than previously thought.
Unfortunately, a definitive diagnosis may be difficult to obtain.
The direct Coombs' test appears to be neither specific nor sensitive in cats.
New techniques, such as flow cytometry and anti-erythrocyte antibody assays, may be helpful in identifying anti-erythrocyte
antibodies in cats with primary hemolytic anemia but are currently not commercially available.
Therefore the diagnosis of primary immune-mediated hemolytic anemia cats is usually made by ruling out all other causes of
anemia with an exhaustive work-up and trial therapy. Treatment with immunosuppressive doses of steroids is the mainstay of
Dr. Hoskins is owner of Docu-Tech Services. He is a diplomate of the American College of Veterinary Internal Medicine with
specialities in small animal pediatrics. He can be reached at (225) 955-3252, fax: (214) 242-2200 or e-mail: firstname.lastname@example.org